文献速递肝病

特利加压素治疗肝硬化急性肾损伤的真实世界应用

Real-World Use of Terlipressin in Cirrhosis and Acute Kidney Injury: Frequent Use Beyond Hepatorenal Syndrome.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-09-08

这项国际前瞻性研究纳入1456例肝硬化急性肾损伤住院患者,其中17%接受特利加压素治疗。仅50%为HRS-AKI,17%为急性肾小管坏死(ATN),ATN患者AKI缓解率最低(29%),且ATN独立预测未缓解和28天死亡。

要点

  • 特利加压素在真实世界中常用于HRS-AKI以外的AKI类型,仅50%为HRS-AKI。
  • ATN患者AKI缓解率仅29%,且独立预测未缓解(OR 2.77)和28天死亡。
  • 特利加压素治疗中20%出现新发呼吸衰竭,肺炎独立预测其发生。

核心结论

  • 特利加压素常超适应证用于肝硬化AKI,ATN患者应答显著低于HRS-AKI,风险可能大于获益。

研究设计与样本

  • 国际前瞻性研究,纳入因失代偿期肝硬化住院的AKI患者,为接受特利加压素治疗者的亚组分析。
  • 共1456例AKI患者,243例(17%)接受特利加压素。

主要发现

  • 特利加压素以持续输注为主(75%);AKI表型:HRS-AKI 50%,ATN 17%,低血容量性25%,其他8%。
  • AKI缓解率49%,ATN最低(29%),HRS-AKI为51%,低血容量性为63%。
  • ATN独立关联AKI未缓解(OR 2.77;95%CI 1.24-6.54;P=.02)。
  • 新发呼吸衰竭20%;肺炎独立预测呼吸衰竭(OR 7.80;95%CI 2.43-26.95;P<.001)。
  • 28天死亡率36%;ATN和医院获得性AKI独立预测28天死亡。

临床怎么用

  • 对肝硬化AKI使用特利加压素前应明确AKI表型,ATN患者应答低且风险可能大于获益。
  • 治疗期间需警惕新发呼吸衰竭,合并肺炎者风险更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Terlipressin is indicated to treat hepatorenal syndrome (HRS)-acute kidney injury (AKI) but is likely used outside this primary indication in clinical practice. We aimed to investigate real-world practice patterns on the use of terlipressin in AKI in cirrhosis. METHODS: International prospective study including patients hospitalized for decompensated cirrhosis. This was a subgroup analysis of patients who received terlipressin to treat AKI. Primary outcome was AKI resolution. Secondary outcomes were respiratory failure and 28-day mortality. RESULTS: Among 1456 patients with AKI, 243 (17%) received terlipressin. Terlipressin was predominantly administered as a continuous infusion (75%). The AKI phenotype was HRS-AKI in 50%, acute tubular necrosis (ATN) in 17%, hypovolemic in 25%, and other in 8%. AKI resolution occurred in 49% of the patients, and was lowest in ATN (29%), followed by HRS-AKI (51%) and hypovolemic (63%). ATN was independently associated with lack of AKI resolution (odds ratio, 2.77; 95% confidence interval, 1.24-6.54; P = .02). De novo respiratory failure occurred in 20% of patients. There were no significant differences in the amount of albumin received nor acute-on-chronic liver failure grade between those who did and did not develop respiratory failure. The presence of pneumonia independently predicted respiratory failure (odds ratio, 7.80; 95% confidence interval, 2.43-26.95; P < .001). Mortality rate at 28 days was 36%; ATN and hospital-acquired AKI independently predicted 28-day mortality. CONCLUSIONS: Terlipressin is often used for treatment of AKI outside its primary indication of HRS-AKI. Compared with patients with HRS-AKI, response to terlipressin is significantly lower in patients with ATN, in whom the risks may outweigh the benefits. Respiratory failure is common but does not seem to be driven by the amount of albumin received nor acute-on-chronic liver failure grade.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ma AT, Juanola A, Patidar KR, et al. Real-World Use of Terlipressin in Cirrhosis and Acute Kidney Injury: Frequent Use Beyond Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2025. PMID: 40930302. doi:10.1016/j.cgh.2025.08.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。